These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 11802588)

  • 1. A claims data approach to defining an episode of care.
    Schulman KA; Yabroff KR; Kong J; Gold KF; Rubenstein LE; Epstein AJ; Glick H
    Pharmacoepidemiol Drug Saf; 2001; 10(5):417-27. PubMed ID: 11802588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A claims data approach to defining an episode of care.
    Schulman KA; Yabroff KR; Kong J; Gold KF; Rubenstein LE; Epstein AJ; Glick H
    Health Serv Res; 1999 Jun; 34(2):603-21. PubMed ID: 10357292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administrative and claims records as sources of health care cost data.
    Riley GF
    Med Care; 2009 Jul; 47(7 Suppl 1):S51-5. PubMed ID: 19536019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constructing episodes of care from encounter and claims data: some methodological issues.
    Wingert TD; Kralewski JE; Lindquist TJ; Knutson DJ
    Inquiry; 1995-1996 Winter; 32(4):430-43. PubMed ID: 8567080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of migraine emergency department utilization in the georgia medicaid population.
    Kwong WJ
    Headache; 2007 Oct; 47(9):1326-33. PubMed ID: 17927649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating Determinants of Multiple Treatment Episodes for Substance Abusers.
    Goodman AC; Hankin JR; Kalist DE; Peng Y; Spurr SJ
    J Ment Health Policy Econ; 2001 Jun; 4(2):65-77. PubMed ID: 11967467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy and medical claims data identified migraine sufferers with high specificity but modest sensitivity.
    Kolodner K; Lipton RB; Lafata JE; Leotta C; Liberman JN; Chee E; Moon C
    J Clin Epidemiol; 2004 Sep; 57(9):962-72. PubMed ID: 15504639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Migraine-diagnosis and treatment in family practice].
    Sigurdardóttir AM; Sigurdsson EL
    Laeknabladid; 2009 Jun; 95(6):433-8. PubMed ID: 19491408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.
    Bigal ME; Serrano D; Reed M; Lipton RB
    Neurology; 2008 Aug; 71(8):559-66. PubMed ID: 18711108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).
    Friedman DS; Quigley HA; Gelb L; Tan J; Margolis J; Shah SN; Kim EE; Zimmerman T; Hahn SR
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5052-7. PubMed ID: 17962457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients.
    Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
    Med Care; 2008 Nov; 46(11):1125-33. PubMed ID: 18953222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT).
    De Diego EV; Lanteri-Minet M
    Cephalalgia; 2005 Mar; 25(3):184-90. PubMed ID: 15689193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.
    Tepper SJ; Dahlöf CG; Dowson A; Newman L; Mansbach H; Jones M; Pham B; Webster C; Salonen R
    Headache; 2004 Oct; 44(9):856-64. PubMed ID: 15447694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J; Fernandes AW; Nelson W
    Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical picture and treatment of subsequent depressive episodes--results of Polish multicenter study].
    Rybakowski J; Kiejna A; Nawacka-Pawlaczyk D; Kargul M
    Psychiatr Pol; 2003; 37(3):419-31. PubMed ID: 13677972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.